Publication:
PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma

Thumbnail Image

Open/View Files

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Hindawi
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Hirsch, Michelle S., and Alessandra F. Nascimento. 2017. “PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma.” Case Reports in Pathology 2017 (1): 6714549. doi:10.1155/2017/6714549. http://dx.doi.org/10.1155/2017/6714549.

Research Data

Abstract

PAX8 is important for embryogenesis of the thyroid, Müllerian system, and upper urinary/renal tract, and expression of PAX8 has been described in carcinomas from each of these sites. The sensitivity and specificity of the polyclonal PAX8 antibody in a large cohort of epithelial tumors as well as lymphomas have been previously determined, the latter because polyclonal PAX8 is known to be immunoreactive in nonneoplastic B-cell lymphocytes which are often used as the positive internal control for immunohistochemistry. In this case report, PAX8 was a diagnostic clue for revising a previous diagnosis of unclassified high grade sarcoma to diffuse large B-cell lymphoma. This case report demonstrates a pitfall for PAX8 immunoreactivity and acts as a reminder that lymphoma should be included in the differential diagnosis of a PAX8 positive, epithelial cell marker negative tumor of unknown primary origin.

Description

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories